Japan Tobacco (JAPAF) 42.3300 $JAPAF
WHO Censorship Tactics Should be Exposed at World Health Assembly
CNW Group - Tue May 24, 1:30AM CDT
As the Annual Summit Takes Place This Week, Global Leaders Have an Opportunity to Scrutinize WHO's definition of transparency and accountability
APAC E-Cigarette and Vaporizer Device Market 2016-2025 - Key Players are MistLife, Smoore Technology Limited, Kanger Tech, First Union, Kimree, Just Fog, ITC & Japan Tobacco
GlobeNewswire - Thu May 12, 2:55AM CDT
Research and Markets has announced the addition of the "APAC E-Cigarette and Vaporizer Device Market - Estimation & Forecast, 2015-2025 Focus on Type, Distribution Channel, and Geography" report to their offering.
22nd Century to Call for National Tobacco Harm Reduction Policy at Tobacco Merchants' Association National Conference
BusinessWire - Fri May 06, 9:30AM CDT
22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced today that on Tuesday, May 10, 2016, Henry Sicignano, III, the Company's President and Chief Executive Officer, will participate in a panel discussion entitled "The Future of Nicotine" at the 101st Annual Meeting of the Tobacco Merchants' Association in Williamsburg, Virginia.
XXII: 0.85 (-0.01)
What Traders Look in a Chart -- Free Research Reports on The Chron Organization, Tencent Holdings, Japan Tobacco and Detour Gold
ACCESSWIRE - Mon Mar 07, 7:05AM CST
NEW YORK, NY / ACCESSWIRE / March 7, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: The Chron Organization (OTC: USAR), Tencent Holdings Ltd. (OTC: TCEHY), Japan Tobacco Inc. (OTC: JAPAY) and Detour Gold Corp. (OTC: DRGDF). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
JTI Again Certified as One of the Top Five Employers in Europe
PR Newswire - Wed Feb 10, 2:00AM CST
Consistent exceptional employee conditions acknowledged in 28 countries
JTI Again Certified as Top Employer in the Middle East
CNW Group - Wed Feb 10, 2:00AM CST
Exceptional employee conditions acknowledged in four countries
APAC E-Cigarette and Vaporizer Device Market - Estimation & Forecast - Expected to Reach $5.37 Billion By 2025
M2 - Fri Feb 05, 6:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/s6h7z9/apac_ecigarette) has announced the addition of the "APAC E-Cigarette and Vaporizer Device Market - Estimation & Forecast 2015-2025" report to their offering. The Asia Pacific e-cigarette device market is expected to grow over $5.37 billion by 2025, at a double digit CAGR from 2016 to 2025. The market will witness a staggering growth until 2018, by when most of the regulatory and policy framework will fall into place. The growth rate will significantly increase thereafter, with significant revenue generation from evolving markets of China, India and Malaysia. Moreover, while disposable e-cigarettes dominated the APAC e-cigarette product market till 2015, rechargeable e-cigarettes, followed by personal vaporizers and Mods will soon take over the top market positions in terms of revenue generation. Although Malaysia dominated the market in 2015, China is expected to become the largest revenue generating country by the end of 2025, while India is expected to grow at the fastest CAGR of 43.6% throughout the forecast period and become the second largest market in the region by 2025. However, the state and federal government's proposals to regulate, heavily tax, or outright ban e-cigarettes are emerging as a key challenge for the market. Further, a growing market of counterfeit products and the unregulated manufacturing process in China are other restraining factors in the e-cigarette market. Companies Mentioned: - Electronic Cigarette Just Fog Co., Ltd. - Firstunion - Innokin Technology Co., Ltd. - Itc Limited - Japan Tobacco, Inc. - Joyetech - Kanger Technology Co., Ltd. - Kimree, Inc - L-Rider Technology Co., Ltd. - Mistlife - Shenzhen Smoore Technology Co., Ltd. - Smokefree - Timiya Technology Co., Ltd Key Topics Covered: 1 Research Scope, Methodology & Description 2 Executive Summary 3 Market Dynamics 4 Industry Analysis 5 Consumer's Perspective and Buyer's Criteria 6 Product Type (Price Bands) 7 Distribution Channel 8 Geography 9 APAC E-Cigarette Market Company Profiles For more information visit http://www.researchandmarkets.com/research/s6...ecigarette
Japan Tobacco International | JT's Consolidated Financial Results for FY2015
M2 - Thu Feb 04, 2:55AM CST
FY2015 demonstrated solid profit growth from continuing operations
Global Cedar Pollen Allergy Therapeutics Development Pipeline Review, H2 2015
M2 - Mon Feb 01, 10:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/gh59r8/cedar_pollen) has announced the addition of the "Cedar Pollen Allergy - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cedar Pollen Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cedar Pollen Allergy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Cedar Pollen Allergy Overview - Therapeutics Development - Pipeline Products for Cedar Pollen Allergy - Overview - Pipeline Products for Cedar Pollen Allergy - Comparative Analysis - Cedar Pollen Allergy - Therapeutics under Development by Companies - Cedar Pollen Allergy - Therapeutics under Investigation by Universities/Institutes - Cedar Pollen Allergy - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Cedar Pollen Allergy - Products under Development by Companies - Cedar Pollen Allergy - Products under Investigation by Universities/Institutes - Cedar Pollen Allergy - Companies Involved in Therapeutics Development - Anergis SA - Biomay AG - Circassia Pharmaceuticals Plc - Immunomic Therapeutics, Inc. - Japan Tobacco Inc. - REGiMMUNE Corporation For more information visit http://www.researchandmarkets.com/research/gh...dar_pollen
AHF Files Federal Lawsuit Against Gilead to Invalidate Patents on Key AIDS Drug
BusinessWire - Tue Jan 26, 2:51PM CST
AIDS Healthcare Foundation (AHF) filed a federal lawsuit today against Gilead Sciences Inc. seeking to invalidate patents on key AIDS drugs held by the Bay Area drug maker. The legal action was filed today in U.S. District Court, Northern District of California, [Case # 3:16-cv-00443] and concerns Tenofovir, a key HIV/AIDS drug which was first synthesized over thirty years ago in the Czech Republic. Tenofovir is a component in Genvoya, Gilead's four-in-one Fixed Dose Combination (FDC) to treat HIV/AIDS patients as well as Gilead's similar predecessor FDC, Stribild.
Identifying Opportunity, Placing Risk - Analyst Notes on Prosiebensat 1 Media, Japan Tobacco, Lenovo Group and Atlantia
ACCESSWIRE - Fri Jan 22, 7:45AM CST
NEW YORK, NY / ACCESSWIRE / January 22, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Prosiebensat 1 Media SE (OTC: PBSFY), Japan Tobacco Inc. (OTC: JAPAY), Lenovo Group Ltd. (OTC: LNVGY) and Atlantia SpA (OTC: ATASY). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
JTI Continues Its Digital Transformation with Long-Term Partner Orange Business Services with Five-Year, $120 Million Contract Renewal
BusinessWire - Wed Jan 20, 4:25AM CST
--Supports JTI transformation and builds on 20-year partnership
ORAN: 17.38 (-0.09)
3 Reasons Reynolds American Inc. Stock Could Fall
Leo Sun, The Motley Fool - Motley Fool - Thu Jan 14, 10:08AM CST
Shares of Reynolds American have rallied 40% over the past 12 months, easily outperforming the S&P 500 and its 6% decline. In a previous article , I discussed why Reynolds and its rival Altria are solid investments for these...
RAI: 51.05 (-0.02), MO: 65.20 (-0.10)
Japan Tobacco International | JT completes acquisition of Natural American Spirit Business outside the United States
M2 - Thu Jan 14, 2:50AM CST
Japan Tobacco Inc. (JT) (TSE: 2914) announced today that the JT Group has completed the acquisition of the Natural American Spirit business outside the United States. The acquisition was announced in the Company's September 29, 2015 statement, "JT acquires Natural American Spirit Business outside the United States."
Global Hyperphosphatemia Drugs Market Growth of 10.71% CAGR by 2019 - Analysis, Technologies & Forecasts 2015-2019
M2 - Thu Dec 17, 4:10AM CST
Research and Markets (http://www.researchandmarkets.com/research/v5pctr/global) has announced the addition of the "Global Hyperphosphatemia Drugs Market 2015-2019" report to their offering. The report, Global Hyperphosphatemia Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global hyperphosphatemia drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market. The report forecasts the global hyperphosphatemia drugs market to grow at a CAGR of 10.71% over the period 2014-2019. Questions Answered: - What will the market size be in 2019 and what will the growth rate be? - What are the key Market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors? Companies Mentioned Include: - Fresenius Medical Care - Keryx Biopharmaceuticals - Sanofi - Shire - Vifor Pharma - Alkem - Amgen - Ardelyx - AstraZeneca - Baxter - Bayer - Chugai Pharmaceutical - Japan Tobacco - Kissei Pharmaceutical - Sandoz - Synthon - Torri Pharmaceutical Report Structure: PART 01: Executive summary PART 02: Scope of the report PART 03: Market research methodology PART 04: Product profiles PART 05: Introduction PART 06: Disease Overview PART 07: Key developments in hyperphosphatemia therapy PART 08: Guidelines for use of phosphate binders PART 09: Pipeline analysis PART 10: Market landscape PART 11: Hyperphosphatemia management market dynamics PART 12: Market segmentation by dosage form PART 13: Market segmentation by formulation PART 14: Geographical segmentation PART 15: Key leading countries PART 16: Market drivers PART 17: Impact of drivers PART 18: Market challenges PART 19: Impact of drivers and challenges PART 20: Market trends PART 21: Vendor landscape PART 22: Key vendor analysis PART 23: Appendix For more information visit http://www.researchandmarkets.com/research/v5pctr/global
AMGN: 160.19 (+1.00), KERX: 6.50 (+0.22)
E-cigarette Market in the US 2015-2019 - Market Segmentation By Product & Distribution Channel
M2 - Wed Dec 16, 8:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/m7j6p9/ecigarette) has announced the addition of the "E-cigarette Market in the US 2015-2019" report to their offering. The report predicts the e-cigarettes market in the US to grow at a CAGR of around 33% during the forecast period. The increased desire among consumers to quit smoking tobacco is the primary driver for the growth of this market. For instance, according to the US government, approximately 480,000 people die in the country every year due to active smoking. E-cigarettes are considered a healthier alternative to tobacco smoking, and, therefore, are becoming popular among end-users. The low cost of e-cigarettes is also expected to contribute to the growth of the market during the forecast period. E-cigarettes are cheaper than traditional cigarettes due to the lack of legitimate taxation on their sale. The wholesale price of a disposable e-cigarette is between USD 2.5 and USD 4.0, whereas rechargeable e-cigarette costs between USD 6 and USD 15. Key Topics Covered: PART 01: Executive summary PART 02: Scope of the report PART 03: Market research methodology PART 04: Introduction PART 05: Worldwide cigarette statistics: Per capita consumption per year PART 06: Market landscape PART 07: Product life cycle analysis PART 08: Market segmentation by product PART 09: Market segmentation by distribution channel PART 10: Market drivers PART 11: Impact of drivers PART 12: Market challenges PART 13: Impact of drivers and challenges PART 14: Market trends PART 15: Vendor landscape PART 16: Other prominent vendors PART 17: Key vendor analysis Companies Mentioned: - Altria Group - CB Distributors - Imperial Tobacco - LOGIC Technology - NJOY - Reynolds American - Ballantyne Brands - British American Tobacco - FIN Branding - Gamucci - Japan Tobacco - Nicotek - RRR Chemicals - Vapor - Victory Electronic Cigarettes - VMR Products - White Cloud. For more information visit http://www.researchandmarkets.com/research/m7j6p9/ecigarette
BTI: 123.30 (+0.54), MO: 65.20 (-0.10)
Renal Anemia Pipeline Report H2 2015 - 25 Companies & 25 Drug Profiles
M2 - Tue Dec 15, 4:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/gpbrhk/renal_anemia) has announced the addition of the "Renal Anemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Renal Anemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Anemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acceleron Pharma, Inc. - Akebia Therapeutics, Inc. - Amgen Inc. - Aprogen, Inc. - Bayer AG - BIOCAD - CCM Duopharma Biotech Bhd. - Chong Kun Dang Pharmaceutical Corp. - Daiichi Sankyo Company, Limited - Dong-A Socio Group - Dr. Reddy's Laboratories Limited - Eli Lilly and Company - FibroGen, Inc. - GlaxoSmithKline Plc - Intas Pharmaceuticals Ltd. - Japan Tobacco Inc. - JCR Pharmaceuticals Co., Ltd. - Jiangsu Hansoh Pharmaceutical Co., Ltd. - Medgenics Inc. - Myungmoon pharmaceutical Co., Ltd. - Panacea Biotec Limited - Pfizer Inc. - ProMetic Life Sciences Inc. - Sandoz International GmbH - Zydus Cadila Healthcare Limited Drug Profiles - Biologic for Renal Anemia - daprodustat - darbepoetin alfa - darbepoetin alfa (recombinant) - DS-1093 - EPO-018B - epoetin - epoetin alfa - epoetin alfa (recombinant) - FG-2216 - JTZ-951 - MDGN-201 - MMP-0101 - molidustat - PBI-1402 - PEG-EPO - Peg-EPO - PEG-EPO - PRS-080 - Recombinant Protein for Renal Anemia - roxadustat - Small Molecule to Inhibit HIF-PH for Renal Anemia - sotatercept - SSS-06 - vadadustat For more information visit http://www.researchandmarkets.com/research/gp...nal_anemia
MDGN: 6.03 (+0.20), PFE: 34.93 (+0.24), AMGN: 160.19 (+1.00), LLY: 74.84 (-0.28), GSK: 42.85 (-0.04), AKBA: 8.76 (-0.08), FGEN: 19.75 (+1.06), XLRN: 37.05 (+0.86)
PharmaPoint: Human Immunodeficiency Virus (HIV) - Global Drug Forecast and Market Analysis to 2023 for the $15 Billion Industry
M2 - Mon Dec 14, 8:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/bx9gn8/pharmapoint) has announced the addition of the "PharmaPoint: Human Immunodeficiency Virus (HIV) - Global Drug Forecast and Market Analysis to 2023" report to their offering. Global HIV Therapeutics Market Value Will Crawl to Almost $15.3 Billion by 2023. The value of the Human Immunodeficiency Virus (HIV) treatment market will increase marginally from just over $14 billion in 2013 to approach $15.3 billion by 2023, representing a low Compound Annual Growth Rate (CAGR) of 0.9% across the nine major markets of the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, and China. While the overall market size will not undergo major changes, the treatment landscape is expected to experience a paradigm shift towards integrase inhibitor drugs and single-tablet regimens (STRs). This shift will be most pronounced in the US, as financial austerity measures remain a primary barrier to growth in the other countries. Moritz Herrmann, Ph.D., says: The market growth will mainly be driven by the introduction of novel drugs, such as STRs with improved tolerability, a reduced pill burden or increased efficacy, and an increasing number of people living with HIV who are treated with antiretroviral therapy (ART). However, due to patient and physician awareness of HIV often being limited, there have been low diagnosis rates, increased disease transmission, and delayed ART administration. During the forecast period, market growth will be limited by patent expirations of several key products, such Gilead Sciences' Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate [TDF]). Furthermore, several countries, such as Germany, China and Brazil, will promote the use of more affordable generic drugs over branded products. However, The report notes that the launches of several STRs, such as ViiV's Triumeq (dolutegravir/abacavir/lamivudine) and Gilead's Quad 2 (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide [TAF]), will help to offset the impact of generics over the next few years. Herrmann continues: Despite these new drugs, the HIV treatment space is still plagued by a range of environmental barriers, such as low patient awareness of the disease, and the social stigma that is associated with it in most countries. Lack of access to medicines and the high cost of therapy still represent major hurdles that must be overcome in order to fully address the global HIV epidemic, the analyst concludes. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Unmet Need and Opportunity 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook 11 Appendix Companies Mentioned - Gilead Sciences - ViiV Healthcare - AbbVie - Merck & Co. - Janssen - Bristol-Myers Squibb - Japan Tobacco - Avexa - TaiMed Biologics - Tobira Therapeutics For more information visit http://www.researchandmarkets.com/research/bx...harmapoint
GILD: 87.60 (+1.45), MRK: 57.17 (+0.53), BMY: 74.29 (+1.40), TBRA: 10.40 (-0.11)
WHO Censorship Tactics Should be Exposed at World Health Assembly
CNW Group - Tue May 24, 1:30AM CDT
As the Annual Summit Takes Place This Week, Global Leaders Have an Opportunity to Scrutinize WHO's definition of transparency and accountability
APAC E-Cigarette and Vaporizer Device Market 2016-2025 - Key Players are MistLife, Smoore Technology Limited, Kanger Tech, First Union, Kimree, Just Fog, ITC & Japan Tobacco
GlobeNewswire - Thu May 12, 2:55AM CDT
Research and Markets has announced the addition of the "APAC E-Cigarette and Vaporizer Device Market - Estimation & Forecast, 2015-2025 Focus on Type, Distribution Channel, and Geography" report to their offering.
22nd Century to Call for National Tobacco Harm Reduction Policy at Tobacco Merchants' Association National Conference
BusinessWire - Fri May 06, 9:30AM CDT
22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced today that on Tuesday, May 10, 2016, Henry Sicignano, III, the Company's President and Chief Executive Officer, will participate in a panel discussion entitled "The Future of Nicotine" at the 101st Annual Meeting of the Tobacco Merchants' Association in Williamsburg, Virginia.
XXII: 0.85 (-0.01)
What Traders Look in a Chart -- Free Research Reports on The Chron Organization, Tencent Holdings, Japan Tobacco and Detour Gold
ACCESSWIRE - Mon Mar 07, 7:05AM CST
NEW YORK, NY / ACCESSWIRE / March 7, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: The Chron Organization (OTC: USAR), Tencent Holdings Ltd. (OTC: TCEHY), Japan Tobacco Inc. (OTC: JAPAY) and Detour Gold Corp. (OTC: DRGDF). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
JTI Again Certified as One of the Top Five Employers in Europe
PR Newswire - Wed Feb 10, 2:00AM CST
Consistent exceptional employee conditions acknowledged in 28 countries
JTI Again Certified as Top Employer in the Middle East
CNW Group - Wed Feb 10, 2:00AM CST
Exceptional employee conditions acknowledged in four countries
APAC E-Cigarette and Vaporizer Device Market - Estimation & Forecast - Expected to Reach $5.37 Billion By 2025
M2 - Fri Feb 05, 6:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/s6h7z9/apac_ecigarette) has announced the addition of the "APAC E-Cigarette and Vaporizer Device Market - Estimation & Forecast 2015-2025" report to their offering. The Asia Pacific e-cigarette device market is expected to grow over $5.37 billion by 2025, at a double digit CAGR from 2016 to 2025. The market will witness a staggering growth until 2018, by when most of the regulatory and policy framework will fall into place. The growth rate will significantly increase thereafter, with significant revenue generation from evolving markets of China, India and Malaysia. Moreover, while disposable e-cigarettes dominated the APAC e-cigarette product market till 2015, rechargeable e-cigarettes, followed by personal vaporizers and Mods will soon take over the top market positions in terms of revenue generation. Although Malaysia dominated the market in 2015, China is expected to become the largest revenue generating country by the end of 2025, while India is expected to grow at the fastest CAGR of 43.6% throughout the forecast period and become the second largest market in the region by 2025. However, the state and federal government's proposals to regulate, heavily tax, or outright ban e-cigarettes are emerging as a key challenge for the market. Further, a growing market of counterfeit products and the unregulated manufacturing process in China are other restraining factors in the e-cigarette market. Companies Mentioned: - Electronic Cigarette Just Fog Co., Ltd. - Firstunion - Innokin Technology Co., Ltd. - Itc Limited - Japan Tobacco, Inc. - Joyetech - Kanger Technology Co., Ltd. - Kimree, Inc - L-Rider Technology Co., Ltd. - Mistlife - Shenzhen Smoore Technology Co., Ltd. - Smokefree - Timiya Technology Co., Ltd Key Topics Covered: 1 Research Scope, Methodology & Description 2 Executive Summary 3 Market Dynamics 4 Industry Analysis 5 Consumer's Perspective and Buyer's Criteria 6 Product Type (Price Bands) 7 Distribution Channel 8 Geography 9 APAC E-Cigarette Market Company Profiles For more information visit http://www.researchandmarkets.com/research/s6...ecigarette
Japan Tobacco International | JT's Consolidated Financial Results for FY2015
M2 - Thu Feb 04, 2:55AM CST
FY2015 demonstrated solid profit growth from continuing operations
Global Cedar Pollen Allergy Therapeutics Development Pipeline Review, H2 2015
M2 - Mon Feb 01, 10:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/gh59r8/cedar_pollen) has announced the addition of the "Cedar Pollen Allergy - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cedar Pollen Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cedar Pollen Allergy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Cedar Pollen Allergy Overview - Therapeutics Development - Pipeline Products for Cedar Pollen Allergy - Overview - Pipeline Products for Cedar Pollen Allergy - Comparative Analysis - Cedar Pollen Allergy - Therapeutics under Development by Companies - Cedar Pollen Allergy - Therapeutics under Investigation by Universities/Institutes - Cedar Pollen Allergy - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Cedar Pollen Allergy - Products under Development by Companies - Cedar Pollen Allergy - Products under Investigation by Universities/Institutes - Cedar Pollen Allergy - Companies Involved in Therapeutics Development - Anergis SA - Biomay AG - Circassia Pharmaceuticals Plc - Immunomic Therapeutics, Inc. - Japan Tobacco Inc. - REGiMMUNE Corporation For more information visit http://www.researchandmarkets.com/research/gh...dar_pollen
AHF Files Federal Lawsuit Against Gilead to Invalidate Patents on Key AIDS Drug
BusinessWire - Tue Jan 26, 2:51PM CST
AIDS Healthcare Foundation (AHF) filed a federal lawsuit today against Gilead Sciences Inc. seeking to invalidate patents on key AIDS drugs held by the Bay Area drug maker. The legal action was filed today in U.S. District Court, Northern District of California, [Case # 3:16-cv-00443] and concerns Tenofovir, a key HIV/AIDS drug which was first synthesized over thirty years ago in the Czech Republic. Tenofovir is a component in Genvoya, Gilead's four-in-one Fixed Dose Combination (FDC) to treat HIV/AIDS patients as well as Gilead's similar predecessor FDC, Stribild.
Identifying Opportunity, Placing Risk - Analyst Notes on Prosiebensat 1 Media, Japan Tobacco, Lenovo Group and Atlantia
ACCESSWIRE - Fri Jan 22, 7:45AM CST
NEW YORK, NY / ACCESSWIRE / January 22, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Prosiebensat 1 Media SE (OTC: PBSFY), Japan Tobacco Inc. (OTC: JAPAY), Lenovo Group Ltd. (OTC: LNVGY) and Atlantia SpA (OTC: ATASY). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
JTI Continues Its Digital Transformation with Long-Term Partner Orange Business Services with Five-Year, $120 Million Contract Renewal
BusinessWire - Wed Jan 20, 4:25AM CST
--Supports JTI transformation and builds on 20-year partnership
ORAN: 17.38 (-0.09)
3 Reasons Reynolds American Inc. Stock Could Fall
Leo Sun, The Motley Fool - Motley Fool - Thu Jan 14, 10:08AM CST
Shares of Reynolds American have rallied 40% over the past 12 months, easily outperforming the S&P 500 and its 6% decline. In a previous article , I discussed why Reynolds and its rival Altria are solid investments for these...
RAI: 51.05 (-0.02), MO: 65.20 (-0.10)
Japan Tobacco International | JT completes acquisition of Natural American Spirit Business outside the United States
M2 - Thu Jan 14, 2:50AM CST
Japan Tobacco Inc. (JT) (TSE: 2914) announced today that the JT Group has completed the acquisition of the Natural American Spirit business outside the United States. The acquisition was announced in the Company's September 29, 2015 statement, "JT acquires Natural American Spirit Business outside the United States."
Global Hyperphosphatemia Drugs Market Growth of 10.71% CAGR by 2019 - Analysis, Technologies & Forecasts 2015-2019
M2 - Thu Dec 17, 4:10AM CST
Research and Markets (http://www.researchandmarkets.com/research/v5pctr/global) has announced the addition of the "Global Hyperphosphatemia Drugs Market 2015-2019" report to their offering. The report, Global Hyperphosphatemia Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global hyperphosphatemia drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market. The report forecasts the global hyperphosphatemia drugs market to grow at a CAGR of 10.71% over the period 2014-2019. Questions Answered: - What will the market size be in 2019 and what will the growth rate be? - What are the key Market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors? Companies Mentioned Include: - Fresenius Medical Care - Keryx Biopharmaceuticals - Sanofi - Shire - Vifor Pharma - Alkem - Amgen - Ardelyx - AstraZeneca - Baxter - Bayer - Chugai Pharmaceutical - Japan Tobacco - Kissei Pharmaceutical - Sandoz - Synthon - Torri Pharmaceutical Report Structure: PART 01: Executive summary PART 02: Scope of the report PART 03: Market research methodology PART 04: Product profiles PART 05: Introduction PART 06: Disease Overview PART 07: Key developments in hyperphosphatemia therapy PART 08: Guidelines for use of phosphate binders PART 09: Pipeline analysis PART 10: Market landscape PART 11: Hyperphosphatemia management market dynamics PART 12: Market segmentation by dosage form PART 13: Market segmentation by formulation PART 14: Geographical segmentation PART 15: Key leading countries PART 16: Market drivers PART 17: Impact of drivers PART 18: Market challenges PART 19: Impact of drivers and challenges PART 20: Market trends PART 21: Vendor landscape PART 22: Key vendor analysis PART 23: Appendix For more information visit http://www.researchandmarkets.com/research/v5pctr/global
AMGN: 160.19 (+1.00), KERX: 6.50 (+0.22)
E-cigarette Market in the US 2015-2019 - Market Segmentation By Product & Distribution Channel
M2 - Wed Dec 16, 8:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/m7j6p9/ecigarette) has announced the addition of the "E-cigarette Market in the US 2015-2019" report to their offering. The report predicts the e-cigarettes market in the US to grow at a CAGR of around 33% during the forecast period. The increased desire among consumers to quit smoking tobacco is the primary driver for the growth of this market. For instance, according to the US government, approximately 480,000 people die in the country every year due to active smoking. E-cigarettes are considered a healthier alternative to tobacco smoking, and, therefore, are becoming popular among end-users. The low cost of e-cigarettes is also expected to contribute to the growth of the market during the forecast period. E-cigarettes are cheaper than traditional cigarettes due to the lack of legitimate taxation on their sale. The wholesale price of a disposable e-cigarette is between USD 2.5 and USD 4.0, whereas rechargeable e-cigarette costs between USD 6 and USD 15. Key Topics Covered: PART 01: Executive summary PART 02: Scope of the report PART 03: Market research methodology PART 04: Introduction PART 05: Worldwide cigarette statistics: Per capita consumption per year PART 06: Market landscape PART 07: Product life cycle analysis PART 08: Market segmentation by product PART 09: Market segmentation by distribution channel PART 10: Market drivers PART 11: Impact of drivers PART 12: Market challenges PART 13: Impact of drivers and challenges PART 14: Market trends PART 15: Vendor landscape PART 16: Other prominent vendors PART 17: Key vendor analysis Companies Mentioned: - Altria Group - CB Distributors - Imperial Tobacco - LOGIC Technology - NJOY - Reynolds American - Ballantyne Brands - British American Tobacco - FIN Branding - Gamucci - Japan Tobacco - Nicotek - RRR Chemicals - Vapor - Victory Electronic Cigarettes - VMR Products - White Cloud. For more information visit http://www.researchandmarkets.com/research/m7j6p9/ecigarette
BTI: 123.30 (+0.54), MO: 65.20 (-0.10)
Renal Anemia Pipeline Report H2 2015 - 25 Companies & 25 Drug Profiles
M2 - Tue Dec 15, 4:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/gpbrhk/renal_anemia) has announced the addition of the "Renal Anemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Renal Anemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Anemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acceleron Pharma, Inc. - Akebia Therapeutics, Inc. - Amgen Inc. - Aprogen, Inc. - Bayer AG - BIOCAD - CCM Duopharma Biotech Bhd. - Chong Kun Dang Pharmaceutical Corp. - Daiichi Sankyo Company, Limited - Dong-A Socio Group - Dr. Reddy's Laboratories Limited - Eli Lilly and Company - FibroGen, Inc. - GlaxoSmithKline Plc - Intas Pharmaceuticals Ltd. - Japan Tobacco Inc. - JCR Pharmaceuticals Co., Ltd. - Jiangsu Hansoh Pharmaceutical Co., Ltd. - Medgenics Inc. - Myungmoon pharmaceutical Co., Ltd. - Panacea Biotec Limited - Pfizer Inc. - ProMetic Life Sciences Inc. - Sandoz International GmbH - Zydus Cadila Healthcare Limited Drug Profiles - Biologic for Renal Anemia - daprodustat - darbepoetin alfa - darbepoetin alfa (recombinant) - DS-1093 - EPO-018B - epoetin - epoetin alfa - epoetin alfa (recombinant) - FG-2216 - JTZ-951 - MDGN-201 - MMP-0101 - molidustat - PBI-1402 - PEG-EPO - Peg-EPO - PEG-EPO - PRS-080 - Recombinant Protein for Renal Anemia - roxadustat - Small Molecule to Inhibit HIF-PH for Renal Anemia - sotatercept - SSS-06 - vadadustat For more information visit http://www.researchandmarkets.com/research/gp...nal_anemia
MDGN: 6.03 (+0.20), PFE: 34.93 (+0.24), AMGN: 160.19 (+1.00), LLY: 74.84 (-0.28), GSK: 42.85 (-0.04), AKBA: 8.76 (-0.08), FGEN: 19.75 (+1.06), XLRN: 37.05 (+0.86)
PharmaPoint: Human Immunodeficiency Virus (HIV) - Global Drug Forecast and Market Analysis to 2023 for the $15 Billion Industry
M2 - Mon Dec 14, 8:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/bx9gn8/pharmapoint) has announced the addition of the "PharmaPoint: Human Immunodeficiency Virus (HIV) - Global Drug Forecast and Market Analysis to 2023" report to their offering. Global HIV Therapeutics Market Value Will Crawl to Almost $15.3 Billion by 2023. The value of the Human Immunodeficiency Virus (HIV) treatment market will increase marginally from just over $14 billion in 2013 to approach $15.3 billion by 2023, representing a low Compound Annual Growth Rate (CAGR) of 0.9% across the nine major markets of the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, and China. While the overall market size will not undergo major changes, the treatment landscape is expected to experience a paradigm shift towards integrase inhibitor drugs and single-tablet regimens (STRs). This shift will be most pronounced in the US, as financial austerity measures remain a primary barrier to growth in the other countries. Moritz Herrmann, Ph.D., says: The market growth will mainly be driven by the introduction of novel drugs, such as STRs with improved tolerability, a reduced pill burden or increased efficacy, and an increasing number of people living with HIV who are treated with antiretroviral therapy (ART). However, due to patient and physician awareness of HIV often being limited, there have been low diagnosis rates, increased disease transmission, and delayed ART administration. During the forecast period, market growth will be limited by patent expirations of several key products, such Gilead Sciences' Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate [TDF]). Furthermore, several countries, such as Germany, China and Brazil, will promote the use of more affordable generic drugs over branded products. However, The report notes that the launches of several STRs, such as ViiV's Triumeq (dolutegravir/abacavir/lamivudine) and Gilead's Quad 2 (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide [TAF]), will help to offset the impact of generics over the next few years. Herrmann continues: Despite these new drugs, the HIV treatment space is still plagued by a range of environmental barriers, such as low patient awareness of the disease, and the social stigma that is associated with it in most countries. Lack of access to medicines and the high cost of therapy still represent major hurdles that must be overcome in order to fully address the global HIV epidemic, the analyst concludes. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Unmet Need and Opportunity 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook 11 Appendix Companies Mentioned - Gilead Sciences - ViiV Healthcare - AbbVie - Merck & Co. - Janssen - Bristol-Myers Squibb - Japan Tobacco - Avexa - TaiMed Biologics - Tobira Therapeutics For more information visit http://www.researchandmarkets.com/research/bx...harmapoint
GILD: 87.60 (+1.45), MRK: 57.17 (+0.53), BMY: 74.29 (+1.40), TBRA: 10.40 (-0.11)
